Novartis files for Gleevec to treat four other cancers

Novartis has applied in the U.S. and European Union to have its Gleevec, which is currently approved for treating types of leukemia and stomach cancers, also approved for use in fighting four other types of cancer. The filings are an indication of a movement under way in the drug industry in which the emphasis of cancer treatment is on genetic mutations now believed to be the cause of cancers, instead of specific body parts, The Wall Street Journal asserts.

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA